New Review on the International Journal of Molecular Sciences

The PI3K/AKT/mTOR pathway is one of the signaling cascades most commonly hijacked by cancer cells. Lymphoma cells are no exceptions. Thus, their pharmacological targeting is being extensively explored. Following their previous work with the dual PI3K/mTOR inhibitor bimiralisib (PQR309) (PMID: 29066507), Dr Chiara Tarantelli and Prof. Francesco Bertoni from IOR, together with PD Anastasios Stathis from the local Oncology Institute of Southern Switzerland, and Dr Antonio Lupia, previous visitin...
More

A new publication by Prof. Francesco Bertoni LAB

Antibody-drug conjugates (ADCs) are an effective therapeutic modality to deliver potent cytotoxic molecules to tumor cells bearing a specific antigen. Following their previous work on the anti-CD19 ADCs huB4-DGN462 and coltuximab ravtansine (SAR3419) (PMID 30733273), the research team led by Prof. Francesco Bertoni has now characterized the novel ADC MEN1309/OBT076 targeting CD205 for its anti- lymphoma activity. The work done by Dr Eugenio Gaudio, Dr Chiara Tarantelli and Colleagues, now pub...
More

New publication by Giuseppina Carbone’s Prostate Cancer Biology group

A new study, published in the journal Cancers describes a novel approach to dissect the intrinsic heterogeneity of prostate tumors and provide predictive information on clinical outcome and treatment response in clinical samples and experimental models. This prostate-specific metagene approach can improve treatment selection and clinical management of prostate cancer patients. Sarah N. Mapelli, Domenico Albino, Maurizia Mello-Grand, Dheeraj Shinde, Manuel Scimeca, Rita Bonfiglio, Elena Bonann...
More

Mitochondrial reprogramming heads stem cell expansion and castration-resistance in prostate cancer – New grant awarded to Prof. Carlo Catapano

New grant awarded by the Swiss Cancer League to the Tumor Biology and Experimental Therapeutics Group headed by the IOR Director Prof. Carlo Catapano. The 3-year project aims at exploring the role of mitochondria in prostate cancer progression and resistance to current therapies. Project details Project ID: KLS-4899-08-2019 PI: Carlo Catapano Project title: Mitochondrial dynamics at the crossroad between stemness and treatment resistance in prostate cancer Prostate cancer is one of...
More

Combinatorial nanomedicines for precision therapy of prostate cancer at the IOR – New grant awarded to Prof. Carlo Catapano

New grant awarded to the Tumor Biology and Experimental Therapeutics Group headed by the IOR Director Prof. Carlo Catapano (http://www.ior.usi.ch). The project Nanoparticle-based delivery and combinatorial therapies for cancer funded by SNSF in the context of the European COST action on Cancer Nanomedicine (CA17140) aims at developing new nanoparticle-based medicine for precision therapy of advanced prostate cancer. The project involves scientific partners in Turkey (Prof. Rana Sanyal, Dep...
More